$582 Million is the total value of Aisling Capital Management LP's 16 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 6.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc (BBIO) | $283,687,000 | +89.5% | 3,989,412 | 0.0% | 48.72% | +1.9% | |
| EIDX | Eidos Therapeutics, Inc. (EIDIX) | $147,847,000 | +160.4% | 1,123,630 | 0.0% | 25.39% | +40.0% | |
| HRMY | HARMONY BIOSCIENCES HLDGS IN (HRMY) | $30,468,000 | +6.6% | 842,815 | 0.0% | 5.23% | -42.7% | |
| SPRB | New | Spruce Biosciences, Inc. (SPRB) | $29,306,000 | – | 1,205,511 | +100.0% | 5.03% | – |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $22,796,000 | +50.7% | 1,025,000 | 0.0% | 3.92% | -19.0% | |
| AVRO | AVROBIO, Inc. (AVRO) | $14,076,000 | +7.1% | 1,009,779 | 0.0% | 2.42% | -42.5% | |
| AGLE | Aeglea Biotherapeutics Inc (AGLE) | $13,309,000 | +11.0% | 1,691,151 | 0.0% | 2.29% | -40.3% | |
| PSTX | POSEIDA THERAPEUTICS INC (PSTX) | $11,445,000 | +23.7% | 1,043,267 | 0.0% | 1.96% | -33.5% | |
| VRNA | Verona Pharma plc (VRNA) | $9,327,000 | +12.2% | 1,332,485 | 0.0% | 1.60% | -39.7% | |
| BCEL | Atreca Inc (BCEL) | $6,261,000 | +15.6% | 387,653 | 0.0% | 1.08% | -37.9% | |
| ACRS | Aclaris Theraputics Inc (ACRS) | $4,105,000 | +151.7% | 634,455 | 0.0% | 0.70% | +35.3% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $2,900,000 | -3.3% | 2,000,000 | 0.0% | 0.50% | -48.0% | |
| OBSV | ObsEva SA (OBSV) | $2,884,000 | -16.1% | 1,386,338 | 0.0% | 0.50% | -54.9% | |
| SNSS | Sunesis Pharmaceuticals, Inc. (SNSS) | $2,010,000 | +59.1% | 1,010,000 | 0.0% | 0.34% | -14.4% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $1,433,000 | -67.5% | 2,718,226 | 0.0% | 0.25% | -82.5% | |
| Sell | Nabriva Therapeutics plc (NBRV) | $462,000 | -54.6% | 191,028 | -90.0% | 0.08% | -75.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-02-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.